Literature DB >> 25032119

Urinary neopterin levels in patients with thyroid cancer.

Serap Soytac Inancli1, Sedat Caner2, Fevzi Balkan2, Abbas Ali Tam2, Gulnur Guler3, Reyhan Ersoy2, Bekir Cakir2.   

Abstract

Increased urinary neopterin concentrations have been described in many cancers. We aimed to evaluate the urinary neopterin levels in thyroid cancer. Sixty-nine patients with thyroid cancer, 76 patients with benign thyroid pathology and 33 healthy subjects were evaluated. First morning urine samples were collected from the patients and normal subjects for neopterin and creatinine measurement and stored at -80 °C until analysed. Neopterin levels were 149.3 (15.2-1,602.2) μmol/mol creatinine in the malignant group, 32 (5.2-275.6) μmol/mol creatinine in the benign group and 9.2 (2.7-78.7) μmol/mol creatinine in normal subjects (p ≤ 0.001). Urinary neopterin levels were significantly higher in patients with thyroid cancer than patients with benign thyroid pathologies and normal subjects. Also the patients with benign thyroid pathologies had a higher urinary neopterin level than the normal subjects. Malignant group was divided to two groups; patients with/without chronic thyroiditis (confirmed histologically). There were 22 (31.9 %) patients with and 47 (68.1 %) patients without chronic thyroiditis. Urinary levels of neopterin didn't differ in both groups (168.6 (21.3-716.8) μmol/mol creatinine and 135.3 (15.2-1,602.2) μmol/mol creatinine respectively; p = 0.381). Urinary neopterin levels are high in thyroid cancer patients independently from the presence of chronic thyroiditis.

Entities:  

Keywords:  Hashimoto’s thyroiditis; Inflammation; Neopterin; Thyroid cancer

Year:  2014        PMID: 25032119      PMCID: PMC4071430          DOI: 10.1007/s12070-014-0710-x

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  38 in total

1.  Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.

Authors:  A G Zeimet; M Widschwendter; C Knabbe; D Fuchs; M Herold; E Müller-Holzner; G Daxenbichler; F A Offner; O Dapunt; C Marth
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  Serum neopterin levels in ovarian tumors.

Authors:  I S Park; Y S Lee; J C Kim; S G Hwang
Journal:  Int J Gynaecol Obstet       Date:  1995-12       Impact factor: 3.561

3.  Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.

Authors:  Randa A K Mahmoud; Hala I El-Gendi; Hanan H Ahmed
Journal:  Clin Biochem       Date:  2005-02       Impact factor: 3.281

4.  Serum neopterin as a prognostic indicator in patients with gastric carcinoma.

Authors:  B Unal; B Kocer; B Altun; S Surmeli; S Aksaray; M Balci; B Ozlu; O Cengiz
Journal:  J Invest Surg       Date:  2009 Nov-Dec       Impact factor: 2.533

5.  The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal.

Authors:  José I Botella-Carretero; Aranzazu Prados; Luis Manzano; María T Montero; Luis Escribano; José Sancho; Héctor F Escobar-Morreale
Journal:  Eur J Endocrinol       Date:  2005-08       Impact factor: 6.664

Review 6.  Role of macrophages in tumour progression.

Authors:  K S Siveen; Girija Kuttan
Journal:  Immunol Lett       Date:  2009-03-09       Impact factor: 3.685

7.  Serum neopterin levels in patients with breast cancer.

Authors:  Yesim Yildirim; Nazan Gunel; Ugur Coskun; Hatice Pasaoglu; Sabahattin Aslan; Abdullah Cetin
Journal:  Med Oncol       Date:  2008-03-05       Impact factor: 3.064

8.  Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma.

Authors:  Clara Ugolini; Fulvio Basolo; Agnese Proietti; Paolo Vitti; Rossella Elisei; Paolo Miccoli; Antonio Toniolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

9.  Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Mitsuyoshi Hirokawa; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.